ClinicalTrials.gg
TerminatedNCT02789098REMOD-TEPUpdated Jun 18, 2026

Relationship Between Left Ventricular Remodeling, Coronary Endothelial Function and Myocardial Fibrosis Using Positron Emission Tomography in Patients With ST-elevation Myocardial Infarction

An interventional study of (15)-O water positron emission tomography and Biomarkers in ST Elevation Myocardial Infarction, sponsored by University Hospital, Caen. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by University Hospital, Caen · Not applicable, Interventional, and Other

Why this study was terminated
lack of patient
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Left ventricular remodeling is a common complication in patients with ST-elevation myocardial infarction (STEMI ) and may lead to heart failure. Hemodynamic, metabolic and inflammatory mechanisms are involved in this pathophysiological process. Recent data demonstrated that remote, noninfarct-related region of the myocardium is also implicated. There is no data about the assessment of coronary endothelial function or myocardial fibrosis in the remote zone in patients with STEMI . The correlation between these parameters and left ventricular remodeling is not known.

02

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • ST Elevation Myocardial Infarction
  • Ventricular remodeling
  • Biomarkers
  • Coronary endothelial function
  • Positron Emission Tomography
03

In context

ST Elevation Myocardial Infarction

850 studies on the registry are indexed under ST Elevation Myocardial Infarction; 197 are open to participants now.

This study's planned enrollment of 30 is below the median of 194 across 527 interventional studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 512 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First ST Elevation Myocardial Infarction
  • Primary Percutaneous Coronary Intervention (TIMI 3)
  • Single vessel coronary artery disease
  • Age over 18 years
  • dated and signed
  • Written and spoken French
  • Beneficiary of social security insurance

Exclusion criteria

Exclusion Criteria:

  • No Primary Percutaneous Coronary Intervention
  • TIMI 0-2 after Primary Percutaneous Coronary Intervention
  • Significant two or three-vessel coronary artery disease (> 70% stenosis in at least one of the other two coronary arteries)
  • Past history of myocardial infarction before STEMI
  • Mechanical complication (ischaemic mitral regurgitation, interventricular septal defect, cardiac tamponade) or clinical signs of heart failure
  • Pregnant and / or lactating
  • Age under 18 years or guardianship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    STEMI

    All patients included in this study (1 arm)

    Other: (15)-O water positron emission tomography and Biomarkers

Interventions

  • Other(15)-O water positron emission tomography and Biomarkers

    Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.

06

What researchers measure

Primary outcomes

  1. Measurement of coronary endothelial function

    3 months following an acute coronary syndrome STEMI an ST segment (segments in myocardial infarcted area and "remote" ) .

    Time frame: 3 months

  2. Measurement of fibrosis

    3 months following an acute coronary syndrome STEMI an ST segment (segments in myocardial infarcted area and "remote" ) .

    Time frame: 3 months

Secondary outcomes

  1. Correlating biomarkers with local and global parameters of coronary endothelial function , inflammation and myocardial fibrosis with early echocardiographic parameters of left ventricular remodeling and cardiac magnetic resonance imaging

    Time frame: 3 months

07

Study locations

1 site
  • CHu de Caen
    Caen, Normandy 14000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02789098
Collaborators
Société Française de Cardiologie
Responsible party
Sponsor
First posted
Jun 2, 2016
Start date
Oct 13, 2016
Primary completion
Oct 29, 2024
Completion
Sep 30, 2025
Last update
Jun 18, 2026

Study contacts

Farzin GF BEYGUI, PhD
study chair · University Hospital, Caen
Alain MA Manrique, PhD
study chair · University Hospital, Caen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion